| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Acetylcholine receptors (agonist). Etiracetam is an acetylcholine agonist. Its mechanism of action may also involve modulation of synaptic vesicle protein SV2A, similar to its active enantiomer levetiracetam, though with lower affinity. The compound is a nootropic drug of the racetam family.
|
|---|---|
| ln Vitro |
Etiracetam is an acetylcholine agonist. It is less active than its S-enantiomer Levetiracetam. The compound has nootropic (cognitive-enhancing) properties and is used as an antiepileptic in research. Its activity is primarily studied in the context of neurological and psychiatric research.
|
| ln Vivo |
Etiracetam has been studied in animal models for its antiepileptic and cognitive-enhancing effects. As a racetam, it is expected to have similar in vivo effects to levetiracetam but with lower potency. The compound is used in research to study the mechanisms of action of racetam drugs.
|
| Enzyme Assay |
In vitro receptor binding assays for Etiracetam typically involve measuring its affinity for the SV2A protein, a synaptic vesicle protein that is the primary target of levetiracetam. Radioligand displacement assays using [3H]-levetiracetam can be used. Acetylcholine receptor binding may also be assessed using radioligand binding assays.
|
| Cell Assay |
The in vitro cellular activity of Etiracetam is evaluated in neuronal cell cultures. Effects on synaptic transmission, neurotransmitter release, and neuronal excitability can be assessed using electrophysiological recordings or calcium imaging. The compound's effects on acetylcholine signaling can be studied in cells expressing acetylcholine receptors.
|
| Animal Protocol |
In vivo animal studies with Etiracetam typically involve administration to rodents via intraperitoneal injection or oral gavage. Models of epilepsy (e.g., pentylenetetrazole-induced seizures) or cognitive impairment (e.g., scopolamine-induced amnesia) are used to assess antiepileptic and nootropic effects. Dosing regimens depend on the specific experimental objectives.
|
| ADME/Pharmacokinetics |
Etiracetam has molecular formula C8H14N2O2 and molecular weight 170.21. It is a racemic mixture and is less active than its S-enantiomer Levetiracetam. The compound is used as a research tool in neurological studies. Storage: under recommended conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for Etiracetam. As a racetam drug, it is expected to have a relatively favorable safety profile based on the clinical use of levetiracetam. However, the racemic mixture may have different toxicity profiles compared to the pure enantiomer. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
Etiracetam is an oxygen-containing organic compound. Etiracetam is currently being investigated in the clinical trial NCT01137110 (comparing the efficacy of short-term versus long-term levetiracetam in preventing seizures following subarachnoid hemorrhage (SAH)). Etiracetam is a pyrrolidone and acetamide derivative primarily used to treat epilepsy and certain motor disorders; it can also be used as a nootropic agent.
Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. It is less active than its S-enantiomer Levetiracetam. The compound is used in research for its antiepileptic and cognitive-enhancing properties. It is not approved for clinical use in most regions, though levetiracetam is approved as an antiepileptic drug. |
| Molecular Formula |
C8H14N2O2
|
|---|---|
| Molecular Weight |
170.21
|
| Exact Mass |
170.105
|
| CAS # |
33996-58-6
|
| Related CAS # |
Levetiracetam;102767-28-2
|
| PubChem CID |
59708
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
395.9±25.0 °C at 760 mmHg
|
| Flash Point |
193.2±23.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.519
|
| LogP |
-0.67
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
203
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HPHUVLMMVZITSG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)
|
| Chemical Name |
2-(2-oxopyrrolidin-1-yl)butanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~734.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (12.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (12.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (12.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8751 mL | 29.3755 mL | 58.7510 mL | |
| 5 mM | 1.1750 mL | 5.8751 mL | 11.7502 mL | |
| 10 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
